alison_doe
New member
Genentech Divarasib Phase III Trial has delivered encouraged results after the company announced positive findings from its Phase III Krascendo 1 study. The landmark head-to-head clinical trial compared the investigational therapy divarasib with the approved first-generation KRAS G12C inhibitors , sotorasib and adagrasib, in patients with previously treated advanced non-small cell lung cancer.
The study achieved both its primary and key secondary endpoints, highlighting divarasib's strong clinical performance. Patients treated with the investigational therapy experienced significant improvements in progression-free survival compared with those receiving currently approved KRAS G12C inhibitors. Interim data also demonstrated meaningful gains in overall survival, reinforcing the treatment's potential to improve patient outcomes.
In addition to its efficacy, divarasib maintains a favorable safety profile throughout the study. Researchers reported that the safety findings were consistent with previous clinical data, with no unexpected safety concerns identified during the trial. The most frequently reported treatment-related adverse events remained, supporting the therapy's continued clinical development.
Levi Garraway, MD, Ph.D., Chief Medical Officer and Head of Global Product Development at Genentech, said the results demonstrate divarasib's ability to deliver superior survival outcomes compared with existing KRAS G12C inhibitors. He noted that the findings have the potential to establish divarasib as a new standard of care for patients with previously treated KRAS G12C-mutated non-small cell lung cancer.
To expand treatment options, Genentech is promoting a broad Phase III clinical development program for divarasib. The company is evaluating the investigational medicine both as a standalone therapy and in chemotherapy-free combination regimens across multiple stages of treatment.
The US Food and Drug Administration (FDA) has already recognized divarasib's potential by granting it Breakthrough Therapy Designation, followed by Orphan Drug Designation in 2026, reflecting the urgent need for improved genetic therapies targeting this specific mutation.
If approved, divarasib could become a preferred treatment option for patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, offering improved survival outcomes while maintaining a moderate safety profile.
Discover Health Tech Insiders for the latest advancements in medical technology and trusted strategic insights shaping the future of tech-driven healthcare transformation.
The study achieved both its primary and key secondary endpoints, highlighting divarasib's strong clinical performance. Patients treated with the investigational therapy experienced significant improvements in progression-free survival compared with those receiving currently approved KRAS G12C inhibitors. Interim data also demonstrated meaningful gains in overall survival, reinforcing the treatment's potential to improve patient outcomes.
In addition to its efficacy, divarasib maintains a favorable safety profile throughout the study. Researchers reported that the safety findings were consistent with previous clinical data, with no unexpected safety concerns identified during the trial. The most frequently reported treatment-related adverse events remained, supporting the therapy's continued clinical development.
Levi Garraway, MD, Ph.D., Chief Medical Officer and Head of Global Product Development at Genentech, said the results demonstrate divarasib's ability to deliver superior survival outcomes compared with existing KRAS G12C inhibitors. He noted that the findings have the potential to establish divarasib as a new standard of care for patients with previously treated KRAS G12C-mutated non-small cell lung cancer.
Addressing an Important Treatment Gap
KRAS G12C-mutated non-small cell lung cancer continues to represent a significant unmet medical need in oncology. The mutation accounts for nearly 14% of NSCLC cases and has historically been associated with poor clinical outcomes, making the development of more targeted therapies a priority for researchers and healthcare providers.To expand treatment options, Genentech is promoting a broad Phase III clinical development program for divarasib. The company is evaluating the investigational medicine both as a standalone therapy and in chemotherapy-free combination regimens across multiple stages of treatment.
The US Food and Drug Administration (FDA) has already recognized divarasib's potential by granting it Breakthrough Therapy Designation, followed by Orphan Drug Designation in 2026, reflecting the urgent need for improved genetic therapies targeting this specific mutation.
Next Steps for Divarasib
Genentech plans to present the complete findings from the Krascendo 1 trial at an upcoming scientific conference. The company also intends to submit the data to global regulatory authorities to support future applications.If approved, divarasib could become a preferred treatment option for patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, offering improved survival outcomes while maintaining a moderate safety profile.
Discover Health Tech Insiders for the latest advancements in medical technology and trusted strategic insights shaping the future of tech-driven healthcare transformation.